Cartesian Therapeutics secured up to $150 million in non-dilutive financing from K2 HealthVentures, with an initial $50 million tranche extending its cash runway into 2028. This funding supports the advancement of multiple clinical trials for its CAR-T therapy Descartes-08 targeting autoimmune diseases like myasthenia gravis and myositis. Key clinical data readouts are expected in the first half of 2027, including Phase 3 AURORA trial topline data for myasthenia gravis in Q1 2027 and subsequent BLA filing planned for mid-2027. The financing also accelerates pre-launch activities, positioning Cartesian for potential commercial launch of Descartes-08.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
DMG Blockchain Solutions announced two strategic investments: one in MeetAmi Innovations, a Canadian fintech offering digital asset wealth management platforms, and another in Atomic47 Labs, an AI company focused on secure, sovereign AI infrastructur...
Gnosis (GNO) surged 13% in 24 hours, closing in on overtaking BONK by market capitalization to reach the 100th largest token spot. GNO's market cap stands at $303.88 million versus BONK's $330.07 million, requiring a price rise to about $125.48 for t...
Broadridge's Tokenization Pulse Survey shows 84% of firms view tokenization as strategically important, with 68% expecting it to reshape markets within 3-5 years. Most firms plan to integrate tokenization into existing infrastructure rather than buil...
Standard Chartered has partnered with Broadcom to modernize its global banking infrastructure by adopting a secure, resilient private cloud using VMware Cloud Foundation. This upgrade supports critical banking services across 54 markets with enhanced...
